What does "AI visibility" mean for my business?

When someone asks ChatGPT, Claude, or Gemini "what is the best..." or "where can I find...", AI gives specific recommendations. AI visibility is a measure of how often — and how positively — these AI platforms mention your business. It's the new version of being on the first page of Google, except now there are no pages — just one answer.

Which AI platforms do you monitor?

Pendium monitors ChatGPT, Claude, Gemini, Grok, Perplexity, DeepSeek, and Google AI Overviews — seven major AI platforms that consumers use to research local services. We run real queries that your customers actually ask and analyze the responses for mentions of your business, competitors, and industry topics.

How does Pendium improve my visibility?

Three ways. First, we identify the exact queries and topics where you're invisible. Second, we generate AI-optimized content — articles, guides, social posts — designed to help AI agents understand your business and recommend your services to the right people. Third, we continuously monitor to track improvement and find new opportunities. Most clients see measurable improvement within 60 days.

How long until I see results?

You'll get your first visibility report within minutes of signing up. Actual visibility improvement varies, but our clients typically see a 47% average improvement within 60 days. Some see results faster — it depends on your current online presence and how competitive your local market is.

Do I need to be technical to use this?

Not at all. Enter your website URL and Pendium handles everything: scanning AI platforms, analyzing your visibility, generating content, and tracking improvement. The dashboard is designed for business owners, not engineers. If you can check your email, you can use Pendium.

What makes this different from SEO?

Traditional SEO optimizes for Google's search rankings — blue links on a results page. AI visibility is different: AI doesn't show links, it gives direct answers. Even if you rank #1 on Google, ChatGPT might recommend a competitor. Pendium optimizes for the new paradigm — making sure AI platforms know about, trust, and recommend your business.

Businesses/Biotechnology / Biopharmaceuticals/Biogen Inc.

AI Visibility & Sentiment

Biogen Inc.

Biogen is a leading multinational biopharmaceutical company dedicated to discovering, developing, and delivering therapies for people living with serious neurological and neurodegenerative diseases. The company is renowned for its pioneering focus on complex areas of the brain and nervous system, maintaining market-leading positions in multiple sclerosis, spinal muscular atrophy, and emerging Alzheimer's treatments.

Active Monitoring

biogen.com

Biotechnology / Biopharmaceuticals

Partial scan

AI Visibility Score

87/100

Excellent

Sentiment Score

75/100

Score by Priority

How often this business is recommended to users across different types of conversations — from direct product queries to broader open-ended conversations where AI could recommend this company's products and services

core

adjacent

aspirational

AI Perception

Key Takeaways

How AI platforms collectively perceive and describe Biogen Inc. today.

Biogen Inc. dominates the competitive landscape for neurodegenerative therapeutics, frequently securing top-tier positions when AI search engines are queried for industry leaders and treatment efficacy. While the brand maintains a commanding presence within its core scientific and clinical niches, there is a distinct visibility gap in holistic patient support and daily management discourse that competitors are beginning to exploit.

Working in your favor

Secures #1 position in AI Overviews for queries related to industry leadership in neuroscience.

High mention rate of 83% among specialized academic neurologists, reflecting strong brand authority in clinical circles.

Consistently referenced in high-intent queries regarding treatment options for spinal muscular atrophy and complex neurodegenerative conditions.

Gaps to close

Total absence in queries regarding daily living aids and supportive care management for neurological patients.

Underperformance in educational content targeting the evaluation of 'breakthrough therapies,' where the brand fails to provide guidance to potential patients or caregivers.

Zero visibility in aspirational category queries where competitors are successfully capturing search intent.

Opportunities

Develop patient-centric educational resources that address the intersection of therapeutic treatment and daily quality of life.

Optimize content to address 'breakthrough therapy' evaluation criteria to ensure Biogen is part of the early-stage decision-making journey.

Expand the editorial footprint to include holistic neurological health management, bridging the gap between clinical efficacy and patient lifestyle.

Highest-Impact Actions

Develop and syndicate comprehensive guides on evaluating breakthrough therapies.

The brand currently misses opportunities to shape the narrative when stakeholders are researching how to assess new treatments, a critical juncture in the buyer journey.

Create content hubs focused on supportive daily living aids for neuro-conditions.

Competitors are gaining ground by expanding into supportive care; establishing authority here will improve the brand's visibility in 'adjacent' and 'aspirational' query spaces.

Produce thought-leadership content on the diagnostic tools used in modern neurology.

Targeting the 'Comprehensive Neurological Health Management' category will reinforce the brand's position as a partner to neurologists throughout the entire patient journey, not just at the treatment phase.

Value Proposition

Deep specialization in high-risk, high-reward neuroscience, focusing R&D almost exclusively on complex and underserved areas of the human brain and nervous system that other firms often avoid.

Overview

Mission

We are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases.

Products & Services

SPINRAZA (nusinersen)LEQEMBI (lecanemab-irmb)TYSABRI (natalizumab)SKYCLARYS (omaveloxolone)VUMERITY (diroximel fumarate)

Current State

Visibility Landscape

A high-level view of how Biogen Inc. performs across AI platforms, broken down by strategic priority level — from core brand queries to growth opportunities.

	ChatGPT	Claude	Gemini	AI Overviews
Reputation1q Brand recognition & direct queries	—	—	—	97
Core4q Product/service category queries	—	—	—	93
Growth Areas4q Adjacent, aspirational & visionary	—	—	—	45

Competitive Landscape

Biogen Inc.10 mentions

Kisunla4 mentions

Namenda4 mentions

Aricept3 mentions

Exelon3 mentions

Razadyne3 mentions

Kesimpta3 mentions

Tyruko3 mentions

Briumvi3 mentions

Lemtrada3 mentions

Neurocrine Biosciences (Ingrezza)3 mentions

Analysis

Insights & Recommended Actions

What's working, what's not, and specific steps to improve Biogen Inc.'s AI visibility.

Key Findings

Strength

Secures #1 position in AI Overviews for queries related to industry leadership in neuroscience.

Strength

High mention rate of 83% among specialized academic neurologists, reflecting strong brand authority in clinical circles.

Strength

Consistently referenced in high-intent queries regarding treatment options for spinal muscular atrophy and complex neurodegenerative conditions.

Recommended Actions

Develop and syndicate comprehensive guides on evaluating breakthrough therapies.

The brand currently misses opportunities to shape the narrative when stakeholders are researching how to assess new treatments, a critical juncture in the buyer journey.

Create content hubs focused on supportive daily living aids for neuro-conditions.

Competitors are gaining ground by expanding into supportive care; establishing authority here will improve the brand's visibility in 'adjacent' and 'aspirational' query spaces.

Produce thought-leadership content on the diagnostic tools used in modern neurology.

Programmatic Testing

Sample Conversations

We programmatically analyze questions that real customers are asking to AI agents and chatbots, extract brand mentions and sentiment, analyze every response, and synthesize the data into an action plan to increase AI visibility.

ChatGPT

Claude

Gemini

AI Overviews

Treatment Options For Neurodegenerative Conditions(3 queries)

“what are the most effective treatments for slowing down alzheimer's progression right now”

1/1 platforms mentioned

Core

AI Overviews

1.Kisunla

2.Leqembi

3.Aricept

4.Exelon

5.Razadyne

+2 more

“best options for managing spinal muscular atrophy in children beyond just physical therapy”

1/1 platforms mentioned

Core

The Specialized Academic Neurologist · Neurologist

AI Overviews

1.Bi-PAP

2.Salanersen

“what are the common injectable or infusion treatments for relapsing multiple sclerosis”

1/1 platforms mentioned

Core

The Specialized Academic Neurologist · Neurologist

AI Overviews

1.Kesimpta

2.Ocrevus (Ocrevus Zunovo)

3.Tysabri

4.Tyruko

5.Briumvi

+2 more

Source Intelligence

Citations

The sources AI platforms cite when recommending this brand. Pendium reverse-engineers what's already proven to be catnip to AI agents, then engineers content that fills gaps and helps agents do their job — which means more citations for you.

Alzheimer's: Medicines help manage symptoms and slow ...

mayoclinic.org

Web1 ref

Medications for Memory, Cognition & Dementia-Related ...

alz.org

Web1 ref

Expanding the Alzheimer's Treatment Landscape: A 2026 ...

brightfocus.org

Web1 ref

What You Should Know About Lecanemab and Donanemab ...

hebrewseniorlife.org

Web1 ref

Alzheimer's Treatments 2025: Here's Every FDA-Approved Therapy ...

beingpatient.com

Web1 ref

How Is Alzheimer's Disease Treated?

nia.nih.gov

Gov1 ref

New treatment for Alzheimer's: A guide for providers

nortonhealthcareprovider.com

Web1 ref

Innovative Alzheimer’s Treatments: What’s New in Managing the ...

wogensenneurology.com

Web1 ref

Lecanemab and Donanemab as Therapies for Alzheimer's ...

pmc.ncbi.nlm.nih.gov

Gov1 ref

Alzheimer's Disease: Symptoms & Treatment

my.clevelandclinic.org

Web1 ref

New drugs transform Alzheimer's research | UCLA Health

uclahealth.org

Web1 ref

New FDA Approved Alzheimer's Treatments

clevelandadrc.org

Web1 ref

Previewing Expected FDA Decisions in Neurology for 2026

neurologylive.com

Web1 ref

The next big breakthroughs in Alzheimer's science and ...

universityofcalifornia.edu

Edu1 ref

FDA Launches Framework for Accelerating Development of ...

fda.gov

Gov1 ref

Engineer content that makes AI agents recommend you

Pendium analyzes how AI platforms perceive your brand, reverse-engineers what they already cite, and continuously publishes content designed to fill gaps and earn more mentions — on autopilot, with you in the loop.

Data generated by Pendium.ai AI visibility scanning. Last scanned March 16, 2026.